Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
An Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin As Treatment For Chemotherapy-Naive Patients With Extensive Disease - Small Cell Lung
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating extensive-stage small cell lung cancer.
PURPOSE: Randomized phase III trial to compare different chemotherapy regimens in treating patients who have extensive-stage small cell lung cancer.
調査の概要
詳細な説明
OBJECTIVES:
- Compare the overall survival of patients with chemotherapy-naive extensive stage small cell lung cancer treated with cisplatin and oral topotecan vs cisplatin and etoposide.
- Compare the response rates, response duration, and time to progression in patients treated with these regimens.
- Compare the tolerability of these regimens in these patients.
- Compare the patient-perceived disease status and well being in patients treated with these regimens.
OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to gender, ECOG performance status (0 vs 1 vs 2), lactate dehydrogenase (less than 1.5 times upper limit of normal (ULN) vs 1.5 times ULN or greater), and country. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive oral topotecan once daily on days 1-5 and cisplatin IV on day 5.
- Arm II: Patients receive cisplatin IV on day 1 and etoposide IV over at least 30 minutes on days 1-3.
Treatment in both arms repeats every 21 days for at least 4 courses in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline, prior to each course, at 4 weeks after study, and then every 4 weeks for 16 weeks.
Patients are followed at 4 weeks, every 4 weeks for 16 weeks, and then every 3 months thereafter.
PROJECTED ACCRUAL: Approximately 760 patients (380 per treatment arm) will be accrued for this study within 18 months.
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44106-5065
- Ireland Cancer Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed extensive stage small cell lung carcinoma (SCLC)
- No prior chemotherapy for SCLC OR
- No chemotherapy within 5 years of diagnosis of SCLC
- Prior radiotherapy to measurable or nonmeasurable disease field allowed provided radiotherapy was completed at least 6 weeks ago and the disease is demonstrated to be progressing
No clinical signs or symptoms of brain and/or leptomeningeal metastases by CT scan or MRI
- Brain and/or leptomeningeal metastases that are asymptomatic on neurologic exam are allowed provided metastases do not require corticosteroid therapy to control symptoms
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- ECOG 0-2
Life expectancy:
- At least 3 months
Hematopoietic:
- Hemoglobin at least 9.0 g/dL
- WBC at least 3,500/mm3
- Platelet count at least 100,000/mm3
- Neutrophil count at least 1,500/mm3
Hepatic:
- Bilirubin no greater than 2.0 mg/dL
- SGOT and SGPT no greater than 2 times the upper limit of normal (ULN) (5 times ULN if liver metastases present)
- Alkaline phosphatase no greater than 2 times ULN (5 times ULN if liver metastases present)
Renal:
- Creatinine no greater than 1.5 mg/dL
- Creatinine clearance at least 60 mL/min
- No pre-existing renal impairment that would preclude cisplatin use
Gastrointestinal:
No clinical evidence of any gastrointestinal (GI) conditions including:
- Removal of a portion of the stomach
- History of recent obstruction of the GI tract
- GI autonomic neuropathy
- Ulcerative colitis
- Crohn's disease
- Malabsorption syndrome
- Treatment with cyclosporine that would alter absorption or GI motility
- No other conditions that would preclude absorption of oral topotecan
Other:
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception for 3 months prior to study, during, and for at least 1 month after study
- No active infection
- No other prior or concurrent malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or localized low-grade prostate cancer
- No other concurrent severe medical problems that would expose the patient to extreme risk or preclude study compliance
- No prior allergic reactions to compounds chemically related to study drugs
- No pre-existing hearing impairment that would preclude cisplatin use
- No overall medical condition for which study drugs would be inappropriate
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- No concurrent immunotherapy for SCLC
Chemotherapy:
- See Disease Characteristics
- No other concurrent chemotherapy for SCLC
Endocrine therapy:
- See Disease Characteristics
- No concurrent hormonal therapy for SCLC
Radiotherapy:
- See Disease Characteristics
- At least 24 hours since prior radiotherapy with no expected bone marrow suppression
- Recovered from prior palliative radiotherapy (e.g, nausea and vomiting from radiation of the epigastrium)
- No concurrent radiotherapy for SCLC
- No concurrent radiotherapy for palliation of bone metastases or CNS lesions unless approved by the investigator
Surgery:
- At least 3 weeks since prior major surgery (a shorter period is allowed if deemed in the best interest of the patient)
Other:
- More than 30 days or 5 half-lives (whichever is longer) since prior investigational drugs
- No other concurrent investigational therapy for SCLC
- No concurrent cyclosporine
- No concurrent drugs that would preclude absorption of oral topotecan
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
アクティブコンパレータ:oral topotecan plus cisplatin IV
oral topotecan once daily on days 1-5 and cisplatin IV on day 5
|
|
実験的:Cisplatin IV plus etoposide IV
Cisplatin IV on day 1 and etoposide IV over at least 30 minutes
|
協力者と研究者
捜査官
- スタディチェア:Nathan Levitan, MD、Case Comprehensive Cancer Center
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- SKF1501
- CWRU-070144
- SB-389
- SB-SKF-104864A
- SB-SKF-1501
- NCI-G02-2092
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
肺癌の臨床試験
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); Highlight Therapeutics積極的、募集していない平滑筋肉腫 | 悪性末梢神経鞘腫瘍 | 滑膜肉腫 | 未分化多形肉腫 | 骨の未分化高悪性度多形肉腫 | 粘液線維肉腫 | II期の体幹および四肢の軟部肉腫 AJCC v8 | III期の体幹および四肢の軟部肉腫 AJCC v8 | IIIA 期の体幹および四肢の軟部肉腫 AJCC v8 | IIIB 期の体幹および四肢の軟部肉腫 AJCC v8 | 切除可能な軟部肉腫 | 多形性横紋筋肉腫 | 切除可能な脱分化型脂肪肉腫 | 切除可能な未分化多形肉腫 | 軟部組織線維肉腫 | 紡錘細胞肉腫 | ステージ I 後腹膜肉腫 AJCC (American Joint Committee on Cancer) v8 | 体幹および四肢の I 期軟部肉腫 AJCC v8 | ステージ... およびその他の条件アメリカ